Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionProduct description

Phase of product development

5 evidence topics · 5 sources

Himalayas-1 registry status and dates
Registry fieldQuoted record
Overall status“Recruiting”
Study start (actual)“2026-08-03”
Primary completion (estimated)“2028-03”
Study completion (estimated)“2030-09”
Expedited program designations

No evidence found.

Regulatory status

No evidence found.

Launch

No evidence found.